表紙:婦人科向け非ホルモン療法の世界市場:標的適応症別 (細菌性膣炎、避妊、子宮内膜症、閉経後骨粗鬆症、子宮筋腫、膣炎など)・分子の種類別 (生体分子、小分子)
市場調査レポート
商品コード
1017503

婦人科向け非ホルモン療法の世界市場:標的適応症別 (細菌性膣炎、避妊、子宮内膜症、閉経後骨粗鬆症、子宮筋腫、膣炎など)・分子の種類別 (生体分子、小分子)

Non-hormonal Therapies for Women's Health Market by Target Indication (Bacterial Vaginosis, Contraception, Endometriosis, Postmenopausal Osteoporosis, Uterine Fibroids, Vaginitis and Others), Type of Molecule (Biologic and Small Molecule),

出版日: | 発行: Roots Analysis | ページ情報: 英文 207 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.77円
婦人科向け非ホルモン療法の世界市場:標的適応症別 (細菌性膣炎、避妊、子宮内膜症、閉経後骨粗鬆症、子宮筋腫、膣炎など)・分子の種類別 (生体分子、小分子)
出版日: 2021年03月31日
発行: Roots Analysis
ページ情報: 英文 207 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

本文中の図説より

世界保健機関 (WHO) によると、何らかの婦人科疾患を発症している女性の数は、15歳から44歳までの女性の約3分の1に達しています。婦人科疾患の治療には、従来はホルモン療法が活用され、大きな成果を上げてきましたが、ホルモン依存性がんを発症するリスクも抱えています。近年は婦人科向け非ホルモン治療薬が数多く開発され、次々と承認・上市されています。将来的には多額の投資や多数の事業提携が見込まれており、更なる成長が期待されています。

当レポートでは、世界の婦人科用非ホルモン療法の市場について分析し、市場の基本構造や背景事情、全体的な市場規模の動向見通し (2021年~2030年)、主要企業の概略と戦略展開状況、主なパイプライン製品の概略と現在の治験動向、資本取引・事業提携の動きなどを調査すると共に、標的適応症別 (細菌性膣炎、避妊、子宮内膜症、閉経後骨粗鬆症、子宮線維症、膣炎など)・分子の種類別 (生体分子、小分子)・投与経路別 (筋肉内、膣内、静脈内、経口、皮下、局所、経皮など)・地域別 (北米、欧州、アジア太平洋ほか) などの詳細動向について取りまとめてお届けいたします。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 イントロダクション

第5章 競合情勢

  • 市場概況
  • 非ホルモン療法市場:開発企業の一覧
    • 創立年度別の分析
    • 企業規模別の分析
    • 地域別の分析
  • 主要企業:製品候補の種類数別の分析
  • 大手製薬企業の取り組み状況

第6章 主な商業化戦略

  • 市場概況
  • 成功する医薬品発売戦略:ROOTSフレームワーク
  • 成功する医薬品発売戦略:製品の差別化
  • 一般的に採用されている商業化戦略:製品の開発段階別
  • 承認された非ホルモン処方薬
  • 婦人科に注力する企業が採用した、主要な商業化戦略
    • 治療薬の承認前に採用された戦略
    • 治療薬の承認中/承認後に採用された戦略
  • 結論

第7章 薬剤プロファイル (第III相)

  • 市場概況
  • Relugolix
  • DARE-BV1 (クリンダマイシンゲル)
  • Ovaprene (R)
  • Yselty (R) (リンザゴリックス)
  • フェゾリネタント
  • BAY1002670 (ビラプリサン)
  • アバロパラチド-TD
  • テルコナゾール (0.4%)
  • SCY-078 (Ibrexafungerp)
  • VT-1161 (オテセコナゾール)
  • MV140 (ウロムネ)
  • Orilissa (TM) (エラゴリックス)
  • EVO100 (アンフォラ)

第8章 治験分析

  • 市場概況
  • 分析範囲・手法
  • 非ホルモン療法:治験分析
    • 治験の登録年度別の分析
    • 治験の状況別の分析
    • 治験段階別の分析
    • 治験の登録年度別・状況別の分析
    • 対象患者の分類別の分析
    • 標的適応症別の分析
    • スポンサーの種類別の分析
    • 地域別の分析
  • 非ホルモン療法:治験に参加した患者の集団別の分析
    • 治験の登録年度別の分析
    • 治験の状況別の分析
    • 試験段階別の分析
    • 地域別の分析
  • 研究計画別の分析
  • 結論
    • 注目すべき新興分子
    • 注目すべき最も重要な試験

第9章 近年の動向

  • 市場概況
  • 事業提携モデル
  • 非ホルモン療法:最近の事業提携
    • 事業提携の年度別の分析
    • 事業提携の種類別の分析
    • 標的適応症別の分析
    • 最も活動的な企業:パートナーシップの数別分析
    • 地域分析
  • 資金の種類
  • 非ホルモン療法:資金調達と投資分析
    • 資金調達の件数別の分析
    • 投資額別の分析
    • 資金調達の種類別の分析
    • 資金の種類別・年度別の分析
    • 資金調達額別・年度別の分析
    • 投資額別・地域別の分析
    • 最も活動的な企業
  • 結論

第10章 市場予測と機会分析

  • 市場概況
  • 分析範囲と制限
  • 予測の主な前提条件と手法
  • 世界の婦人科向け非ホルモン療法の市場
    • 非ホルモン療法市場:標的適応症別の分析
    • 非ホルモン療法市場:分子の種類別の分析
    • 非ホルモン療法市場:投与経路別の分析
    • 非ホルモン療法市場:地域別の分析
  • 婦人科向け非ホルモン療法:付加価値創出額の分析
    • 細菌性膣炎
    • 避妊
    • 子宮内膜症
    • 閉経後骨粗鬆症
    • 子宮筋腫
    • 血管運動症状
  • 婦人科向け非ホルモン療法:製品別の売上高の予測
    • Nuvessa (TM) (メトロニダゾール)
    • VivaGel (TM) (SPL 7013)
    • Solosec (TM) (セクニダゾール)
    • Tymlos (TM) (アバロパラチド)
    • Orilissa (TM)
    • Osphena (R) (オスペミフェン)
    • Evenity (TM)(Romosozumab-aqqg)
    • Esmya (R) and Fibristal (R) (ウリプリスタルアセテート)
    • Phexxi (TM) (アンフォラ)
    • Oriahnn (TM)
    • Relugolix
    • DARE-BV1 (クリンダマイシンゲル)
    • Ovaprene (R)
    • Yselty (R) (リンザゴリックス)
    • Fezolinetant
    • BAY1002670 (ビラプリサン)
    • アバロパラチド-TD
    • テルコナゾール (0.4%)
    • SCY-078 (Ibrexafungerp)
    • VT-1161 (オテセコナゾール)
    • MV140 (ウロムネ)
    • EVO100

第11章 結論

第12章 付録 (1):集計データ

第13章 付録 (2):企業一覧

図表

List Of Tables

  • Table 3.1 Women's Health-related Conditions: Menopause
  • Table 3.2 Available Treatment Modalities: Surgeries
  • Table 3.3 Available Treatment Modalities: Hormonal Therapies
  • Table 4.1 Non-hormonal Therapies Market: Development Pipeline
  • Table 5.1 Non-hormonal Therapies Market: List of Developers
  • Table 6.1 Solosec™: Presentations in Conferences Before Product Approval
  • Table 6.2 Orilissa™: Presentations in Conferences Before Product Approval
  • Table 6.3 Evenity™: Presentations in Conferences Before Product Approval
  • Table 6.4 Phexxi™: Presentations in Conferences Before Product Approval
  • Table 6.5 Oriahnn™: Presentations in Conferences Before Product Approval
  • Table 6.6 Tymlos™: Presentations in Conferences After Product Approval
  • Table 6.7 Phexxi™: Presentations in Conferences After Product Approval
  • Table 6.8 Approved Non-hormonal Therapies: Comparison of Patient Support Services Available on Product Websites
  • Table 7.1 Non-hormonal Therapy Market: List of Phase III Products
  • Table 7.2 Drug Profile: Relugolix (Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.3 Drug Profile: DARE-BV1 (Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.4 Drug Profile: Ovaprene® (Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.5 Drug Profile: Yselty® (Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.6 Drug Profile: Fezolinetant (Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.7 Drug Profile: BAY1002670 (Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.8 Drug Profile: Abaloparatide-TD (Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.9 Drug Profile: Terconazole (0.4%) (Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.10 Drug Profile: SCY-078(Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.11 Drug Profile: VT-1161(Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.12 Drug Profile: MV140 (Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.13 Drug Profile: Orilissa (Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 7.14 Drug Profile: EVO100 (Overview of Drug, Current Development Status and Clinical Trial Results)
  • Table 8.1 Clinical Trial Analysis: Emerging Molecules
  • Table 8.2 Clinical Trial Analysis: Prominent Ongoing Studies
  • Table 9.1 Non-hormonal Therapy Market: List of Partnerships and Collaborations, Pre 2013-2021
  • Table 9.2 Non-hormonal Therapy Market: List of Funding and Investments, 2016-2020
  • Table 10.1 Non-hormonal Therapies: Expected Launch Years of Advanced Stage Drug Candidates
  • Table 10.2 Nuvessa™: Target Patient Population
  • Table 10.3 Nuvessa™: Net Present Value (USD Million)
  • Table 10.4 VivaGel™: Target Patient Population
  • Table 10.5 VivaGel™: Net Present Value (USD Million)
  • Table 10.6 Solosec™: Target Patient Population
  • Table 10.7 Solosec™: Net Present Value (USD Million)
  • Table 10.8 Tymlos™: Target Patient Population
  • Table 10.9 Tymlos™: Net Present Value (USD Million)
  • Table 10.10 Orilissa™: Target Patient Population
  • Table 10.11 Orilissa™: Net Present Value (USD Million)
  • Table 10.12 Osphena®: Target Patient Population
  • Table 10.13 Osphena®: Net Present Value (USD Million)
  • Table 10.14 Evenity™: Target Patient Population
  • Table 10.15 Evenity™: Net Present Value (USD Million)
  • Table 10.16 Esmya® and Fibristal®: Target Patient Population
  • Table 10.17 Esmya® and Fibristal®: Net Present Value (USD Million)
  • Table 10.18 Phexxi™: Target Patient Population
  • Table 10.19 Phexxi™: Net Present Value (USD Million)
  • Table 10.20 Oriahnn™: Target Patient Population
  • Table 10.21 Oriahnn™: Net Present Value (USD Million)
  • Table 10.22 Relugolix: Target Patient Population
  • Table 10.23 Relugolix: Net Present Value (USD Million)
  • Table 10.24 DARE-BV1: Target Patient Population
  • Table 10.25 DARE-BV1: Net Present Value (USD Million)
  • Table 10.26 Ovaprene®: Target Patient Population
  • Table 10.27 Ovaprene®: Net Present Value (USD Million)
  • Table 10.28 Yselty®: Target Patient Population
  • Table 10.29 Yselty®: Net Present Value (USD Million)
  • Table 10.30 Fezolinetant: Target Patient Population
  • Table 10.31 Fezolinetant: Net Present Value (USD Million)
  • Table 10.32 BAY1002670: Target Patient Population
  • Table 10.33 BAY1002670: Net Present Value (USD Million)
  • Table 10.34 Abaloparatide-TD: Target Patient Population
  • Table 10.35 Abaloparatide-TD: Net Present Value (USD Million)
  • Table 10.36 Terconazole (0.4%): Target Patient Population
  • Table 10.37 Terconazole (0.4%): Net Present Value (USD Million)
  • Table 10.38 SCY-078: Target Patient Population
  • Table 10.39 SCY-078: Net Present Value (USD Million)
  • Table 10.40 VT-1161: Target Patient Population
  • Table 10.41 VT-1161: Net Present Value (USD Million)
  • Table 10.42 MV140: Target Patient Population
  • Table 10.43 MV140: Net Present Value (USD Million)
  • Table 10.44 EVO100: Target Patient Population
  • Table 10.45 EVO100: Net Present Value (USD Million)
  • Table 13.1 Non-hormonal Therapies: Distribution by Phase of Development
  • Table 13.2 Non-hormonal Therapies: Distribution by Type of Molecule
  • Table 13.3 Non-hormonal Therapies: Distribution by Target Indication
  • Table 13.4 Non-hormonal Therapies: Distribution by Phase of Development and Target Indication
  • Table 13.5 Non-hormonal Therapies: Distribution by Type of Molecule and Target Indication
  • Table 13.6 Non-hormonal Therapies: Distribution by Purpose of Therapy
  • Table 13.7 Non-hormonal Therapies: Distribution by Target Women Population
  • Table 13.8 Non-hormonal Therapies: Distribution by Mechanism of Action
  • Table 13.9 Non-hormonal Therapies: Distribution by Route of Administration
  • Table 13.10 Non-hormonal Therapies: Distribution by Special Designation(s) Awarded
  • Table 13.11 Non-hormonal Therapy Developers: Distribution by Year of Establishment
  • Table 13.12 Non-hormonal Therapy Developers: Distribution by Company Size
  • Table 13.13 Non-hormonal Therapy Developers: Distribution by Location of Headquarters
  • Table 13.14 Non-hormonal Therapy Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
  • Table 13.15 Non-hormonal Therapy Developers: Big Pharma Initiatives
  • Table 13.16 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre 2013-2020
  • Table 13.17 Clinical Trial Analysis: Distribution by Trial Status
  • Table 13.18 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 13.19 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 13.20 Clinical Trial Analysis: Distribution by Target Patient Segment
  • Table 13.21 Clinical Trial Analysis: Distribution by Target Indication
  • Table 13.22 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Table 13.23 Clinical Trial Analysis: Distribution by Geography
  • Table 13.24 Clinical Trial Analysis: Distribution by Geography, Pre-2017 and Post 2017
  • Table 13.25 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
  • Table 13.26 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
  • Table 13.27 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Table 13.28 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Location of Trial Site
  • Table 13.29 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography , Pre-2017 and Post 2017
  • Table 13.30 Clinical Trial Analysis: Distribution by Study Design
  • Table 13.31 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2021
  • Table 13.32 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 13.33 Partnerships and Collaborations: Cumulative Trend by Year and Type of Collaboration, 2013-2021
  • Table 13.34 Partnerships and Collaborations: Distribution by Type of Acquisition / Merger
  • Table 13.35 Partnerships and Collaborations: Distribution by Focus Area
  • Table 13.36 Partnerships and Collaborations: Distribution by Target Indication
  • Table 13.37 Most Active Players: Distribution by Number of Partnerships
  • Table 13.38 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 13.39 Funding and Investment Analysis: Cumulative Year-wise Distribution by Number of Instances, 2016-2020
  • Table 13.40 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, 2016-2020 (USD Million)
  • Table 13.41 Funding and Investment Analysis: Distribution by Type of Funding
  • Table 13.42 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Table 13.43 Funding and Investment Analysis: Distribution by Year and Funding Amount (USD Million)
  • Table 13.44 Funding and Investment Analysis: Distribution by Geography
  • Table 13.45 Funding and Investment Analysis: Regional Distribution of Funding Instances
  • Table 13.46 Most Active Players: Distribution by Number of Funding Instances, 2016-2020
  • Table 13.47 Most Active Players: Distribution by Amount Invested, 2016-2020 (USD Million)
  • Table 13.48 Funding and Investment Summary, 2016-2020 (USD Million)
  • Table 13.49 Global Non-hormonal Therapies for Women's Health Market, 2021-2030: Base Case Scenario (USD Million)
  • Table 13.50 Non-hormonal Therapies Market: Distribution by Target Indication, 2021, 2025 and 2030
  • Table 13.51 Non-hormonal Therapies Market: Distribution by Type of Molecule, 2021, 2025 and 2030
  • Table 13.52 Non-hormonal Therapies Market: Distribution by Route of Administration, 2021, 2025 and 2030
  • Table 13.53 Non-hormonal Therapies Market: Distribution by Geography, 2021, 2025 and 2030
  • Table 13.54 Nuvessa™ Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.55 VivaGel™ Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.56 Solosec™ Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.57 Tymlos™ Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.58 Orilissa™ Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.59 Osphena® Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.60 Evenity™ Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.61 Esmya® and Fibristal® Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.62 Phexxi™ Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.63 Oriahnn™ Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.64 Relugolix Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.65 DARE-BV1 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.66 Ovaprene® Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.67 Yselty® Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.68 Fezolinetant Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.69 BAY1002670 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.70 Abaloparatide-TD Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.71 Terconazole (0.4%) Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.72 SCY-078 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.73 VT-1161 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.74 MV140 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 13.75 EVO100 Sales Forecast (Till 2030): Conservative, Base and Optimistic Scenarios (USD Million)

List Of Companies

The following companies / institutes / government bodies and organizations have been mentioned in this report.

  • 1. AbbVie
  • 2. Actavis
  • 3. Adjuvant Capital
  • 4. Aisling Capital
  • 5. Allergan
  • 6. Amgen
  • 7. Amplity Health
  • 8. Arcadia Securities
  • 9. Aspire Capital Fund
  • 10. Astellas Pharma
  • 11. Avomeen
  • 12. Azure Biotech
  • 13. Bayer
  • 14. BB Biotech
  • 15. Boehringer Ingelheim
  • 16. Broadfin Capital
  • 17. Brookline Capital Markets
  • 18. Cantor Fitzgerald
  • 19. Ceek Women's Health
  • 20. Celmatix
  • 21. Chugai Pharmaceutical
  • 22. Cidara Therapeutics
  • 23. DAFNA Capital Management
  • 24. Daré Bioscience
  • 25. Duchesnay
  • 26. Eli Lilly
  • 27. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
  • 28. Evofem Biosciences
  • 29. Evotec
  • 30. Exeltis
  • 31. Ferring Pharmaceuticals
  • 32. First Manhattan Co.
  • 33. Forest Laboratories
  • 34. Fougera Pharmaceuticals
  • 35. Gedea Biotech
  • 36. Gedeon Richter
  • 37. Ghost Tree Capital
  • 38. Great Point Partners
  • 39. Guggenheim Securities
  • 40. H.C. Wainwright & Co.
  • 41. Hammock Pharmaceuticals (acquired by Element Nutritional Sciences)
  • 42. Hansoh Pharma
  • 43. Health Decisions
  • 44. Hennepin Life Sciences
  • 45. Inmunotek
  • 46. Inovio Pharmaceuticals
  • 47. Intralytix, the Eliava Foundation
  • 48. ITF Pharma
  • 49. Jiangsu Hengrui Medicine
  • 50. KaNDy Therapeutics (acquired by Bayer)
  • 51. Kindeva Drug Delivery
  • 52. Kissei Pharmaceutical
  • 53. Korea Investment Partners (KIP)
  • 54. Ladenburg Thalmann
  • 55. Ligand Pharmaceuticals
  • 56. Lupin Pharmaceuticals
  • 57. Medtech4Health
  • 58. Merck Sharp & Dohme
  • 59. Milana Pharm
  • 60. Mitsubishi Tanabe Pharma
  • 61. Medical Research Commercialisation Fund (MRCF)
  • 62. Mycovia Pharmaceuticals
  • 63. Myovant Sciences
  • 64. National Holdings
  • 65. National Securities Corporation
  • 66. Neurocrine Biosciences
  • 67. New Enterprise Associates
  • 68. New Leaf Venture Partners
  • 69. NovaDigm Therapeutics
  • 70. Novartis Pharmaceuticals
  • 71. Noven Pharmaceuticals
  • 72. ObsEva
  • 73. Ogeda
  • 74. Omega Funds
  • 75. Oxford Finance
  • 76. PDL BioPharma
  • 77. Pfizer
  • 78. Prosight Capital
  • 79. Puissance Capital
  • 80. QUE Oncology
  • 81. Radius Health
  • 82. Repros Therapeutics (acquired by Allergan)
  • 83. Roche
  • 84. Sanofi-Aventis
  • 85. SCYNEXIS
  • 86. Shionogi
  • 87. Sofinnova Ventures
  • 88. Sphera Global Healthcare Fund
  • 89. Square 1 Bank
  • 90. Starpharma
  • 91. Strategic Science & Technologies
  • 92. Sumitomo Dainippon Pharma
  • 93. Swelife
  • 94. Symbiomix Therapeutics (acquired by Lupin)
  • 95. Takeda Pharmaceutical
  • 96. TriLogic Pharma
  • 97. Uniseed
  • 98. Venrock Healthcare Capital Partners
  • 99. Vinnova Financing
  • 100. Vinnova Grants
  • 101. WBB Securities
  • 102. Woodford Investment Management
  • 103. Xanodyne Pharmaceuticals
  • 104. Yaso Therapeutics
目次

Title:
Non-hormonal Therapies for Women's Health Market
by Target Indication (Bacterial Vaginosis, Contraception, Endometriosis, Postmenopausal Osteoporosis, Uterine Fibroids, Vaginitis and Others), Type of Molecule (Biologic and Small Molecule), Purpose of Therapy (Treatment of Disease and Management of Symptoms), Mechanism of Action (Antagonist, Agonist, Inhibitor and Modulator), Route of Administration, and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2030.

VISUALS

Overview:

According to the World Health Organization (WHO), sexual and reproductive health-related conditions represent around one third of all clinical conditions prevalent among women between the ages of 15 and 44 years. The human female reproductive system is complex and governed primarily by two hormones, estrogen and progesterone. Any imbalance in the levels of these hormones materializes in the form of a disease, and / or mood related disorders; in fact, women are more prone to experiencing various forms of anxiety, depression and certain physical symptoms that cannot yet be explained medically, as compared to men. Since hormones are responsible for almost all of the concerns associated with reproductive health, a number of hormone regulating interventions have been developed, and are available, for the treatment / prevention of the clinical conditions that are unique to women. This form of therapy has been proven to be both viable and effective, and have been in use since the 1960s. Such therapies gained better traction as mainstream healthcare solutions after clinical trials were conducted, proving their efficacy, in the late 1990s. Despite the vast success of using hormones as therapeutics, later studies reflected a positive correlation between the use of such interventions and several unwanted side effects, including the risk of developing hormone dependent cancers.

In recent years, the development and introduction of non-hormonal alternatives has revolutionized women's healthcare. Brisdelle® was the first of such products, approved in 2013 for the management of hot flashes in menopausal women. Till date, 21 non-hormonal therapies (recent examples include Oriahnn™, Phexxi™ and Esmya®) have been approved. Further, several such non-hormonal product candidates are under evaluation across different stages of product development. The inherent advantages of non-hormonal therapies, such as better safety profile, ability to maintain hormonal balance and relatively short treatment courses, over their hormonal counterparts have been demonstrated both in clinical trials and post product approval studies. As a result, such products are currently preferred over hormone-based therapies, and the non-hormonal therapy pipeline is expected to continue to steadily expand over the coming years.It is worth highlighting that significant partnership activity has been observed in this market, with several stakeholders entering into strategic collaborations to support the ongoing product development and commercialization initiatives of such products. In the foreseen future, promising results from the ongoing clinical research initiatives are likely to bring in more investments to support product development activity in this upcoming market segment. Therefore, we are led to anticipate significant growth in this domain in the coming years.

Scope of the Report:

The "Non-hormonal Therapies for Women's Health Market by Target Indication (Bacterial Vaginosis, Contraception, Endometriosis, Postmenopausal Osteoporosis, Uterine Fibroids, Vaginitis and Others), Type of Molecule (Biologic and Small Molecule), Purpose of Therapy (Treatment of Disease and Management of Symptoms), Mechanism of Action (Antagonist, Agonist, Inhibitor and Modulator), Route of Administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others), and Key Geographical Regions (North America, Europe and Asia-Pacific): Industry Trends and Global Forecasts, 2021-2030" report features an extensive study of the current market landscape of non-hormonal therapies, primarily focusing on prescription drugs. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:

  • A detailed review of the overall market landscape of non-hormonal therapies, including information on their current phase of development (marketed, clinical, preclinical and discovery) , type of molecule (biologic and small molecule) ,target indication (bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others) , purpose of therapy (treatment of disease and management of symptoms) , target women population (adult, postmenarchal and premenopausal female, postmenopausal female) , mechanism of action (antagonists, agonists, inhibitors and modulators) , route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others) and special drug designation(s)awarded (if any).
  • A detailed review of the players engaged in the development of non-hormonal therapies, along with information on their year of establishment, company size, location of headquarters and regional landscape.
  • An elaborate discussion on the various commercialization strategies that can be adopted by drug developers engaged in this domain, across different stages of therapy development, including prior to drug launch, at / during drug launch and post-marketing of the drug.
  • Detailed profiles of phase III non-hormonal therapies. Each drug profile features a brief overview of the therapy, along with information on their current development status, route of administration, primary target indication, dosage, mechanism of action, clinical trials, clinical trial results, collaborations and special drug designation(s) received(if any).
  • A detailed geographical clinical trial analysis of completed and ongoing studies of non-hormonal therapies, based on several relevant parameters, such as trial registration year, trial status, trial phase, target indication, geography, type of sponsor, prominent treatment sites and enrolled patient population.
  • An analysis of the various partnerships that have been inked by stakeholders engaged in the development of non-hormonal therapies, during the period pre2013-2020, including research agreements, research and development agreements, contract manufacturing agreements, licensing agreements and other relevant types of deals. It further features a detailed analysis of the investments made, including award / grant, seed financing, venture capital financing, debt financing and others, in companies engaged in this domain.

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated with non-hormonal therapies, over the next decade. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided informed estimates on the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity across (A) target indication (bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others) , (B) type of molecule (biologic and small molecule), (C) route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others), (D) key geographical regions (North America, Europe and Asia-Pacific) . In addition, the chapter presents indication specific value creation analysis. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading industry players engaged in the development of non-hormonal therapies?
  • How many non-hormonal therapy candidates form the current development pipeline? Which key women's health related disease indications are targeted by such products?
  • Which commercialization strategies are most commonly adopted by non-hormonal therapy developers, across different stages of product development?
  • Which partnership models are commonly adopted by stakeholders engaged in this domain?
  • What are the key value drivers of the merger and acquisition activity in the non-hormonal therapies industry?
  • Who are the key stakeholders that have actively made investments in the non-hormonal therapies domain?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Chapter Outlines:

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the non-hormonal therapies for women's health market and its likely evolution in the short to mid term and long term.

Chapter 3 provides a general overview of non-hormonal therapies, including a discussion on the key historical milestones in their development. It further includes an overview of the clinical conditions associated with women's health. Furthermore, it outlines various available treatment modalities for women's health related conditions (namely surgeries, hormonal therapies and non-hormonal therapies), with key focus on non-hormonal treatment options and prescription therapies. The chapter concludes with a discussion on the risks and benefits associated with non-hormonal therapies, along with demonstrating their future potential in the market.

Chapter 4 presents a detailed assessment of the current market landscape of non-hormonal therapies along with information on the industry players active in the domain of women's health. In addition, it features an in-depth analysis of the pipeline molecules, based on a several relevant parameters, such as, current phase of development (marketed, clinical, preclinical and discovery), type of molecule (biologic and small molecule), target indication(bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others), purpose of therapy (treatment of disease and management of symptoms), target women population (adult, postmenarchal and premenopausal female, postmenopausal female), mechanism of action (antagonists, agonists, inhibitors and modulators), route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others)and special drug designation(s) awarded (if any).

Chapter 5 provides a detailed review of the players engaged in the development of non-hormonal therapies, along with information on their year of establishment, company size, location of headquarters, and regional landscape.

Chapter 6 features an elaborate discussion on the various strategies that can be adopted by therapy developers engaged in this domain, across key commercialization stages, including prior to drug launch, during drug launch and post-launch. In addition, it presents an in-depth analysis of the key commercialization strategies that have been adopted by developers of non-hormonal therapies approved during the period 2017-2020.

Chapter 7 provides detailed profiles of phase III non-hormonal therapies. Each drug profile provides information on their current development status, route of administration, primary target indication, dosage, mechanism of action, clinical trials, clinical trial results, collaborations and special drug designation(s) received (if any).

Chapter 8 presents a detailed, geographical clinical trial analysis of completed and ongoing studies focused on non-hormonal therapies, based on several relevant parameters, such as trial registration year, trial status, trial phase, target indication, geography, type of sponsor, prominent treatment sites and enrolled patient population.

Chapter 9 features an elaborate analysis and discussion of the various collaborations and partnerships that have been inked amongst players engaged in the development of non-hormonal therapies, during the period pre2013 - 2020. It includes a brief description on the various types of partnership models including research agreements, research and development agreements, contract manufacturing agreements, licensing agreements and other relevant types of deals, that have been adopted by stakeholders in this domain. Furthermore, we have provided a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents. In addition, the chapter presents details on various funding instances, investments and grants reported within the non-hormonal therapy domain. The chapter includes information on various types of investments, such as seed financing, debt financing, grants, venture capital financing, and others, received by the companies between pre 2013 and 2020, highlighting the growing interest of the strategic investors in this market.

Chapter 10 presents an elaborate market forecast analysis, highlighting the future potential of the market till the year 2030. It also includes future sales projections of non-hormonal therapies that are either marketed or in advanced stage of clinical development (phase III). Sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of (A) target indication (bacterial vaginosis, contraception, endometriosis, postmenopausal osteoporosis, uterine fibroids, vaginitis and others), (B) type of molecule (biologic and small molecule), (C) route of administration (intramuscular, intravaginal, intravenous, oral, subcutaneous, topical, transdermal and others), (D) key geographical regions (North America, Europe and Asia-Pacific). In addition, the chapter presents indication specific value creation analysis.

Chapter 11 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the non-hormonal therapy market.

Chapter 12 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 13 is an appendix, which provides the list of companies mentioned in the report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Women's Health and Affiliated Clinical Conditions
    • 3.2.1. Key Milestones in the Treatment of Women's Health-related Disorders
  • 3.3. Women's Health-related Conditions
  • 3.4. Available Treatment Modalities
    • 3.4.1. Surgery
    • 3.4.2. Hormonal Therapies
    • 3.4.3. Non-Hormonal Therapies
  • 3.5. Future Perspectives

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. Non-hormonal Therapies Market: Pipeline
    • 4.2.1. Analysis by Phase of Development
    • 4.2.2. Analysis by Type of Molecule
    • 4.2.3. Analysis by Target Indication
    • 4.2.4. Analysis by Phase of Development and Target Indication
    • 4.2.5. Analysis by Type of Molecule and Target Indication
    • 4.2.6. Analysis by Purpose of Therapy
    • 4.2.7. Analysis by Target Women Population
    • 4.2.8. Analysis by Mechanism of Action
    • 4.2.9. Analysis by Route of Administration
    • 4.3.1. Analysis by Special Designation(s) Awarded

5. COMPETITIVE LANDSCAPE

  • 5.1. Chapter Overview
  • 5.2. Non-hormonal Therapies Market: List of Developers
    • 5.2.1. Analysis by Year of Establishment
    • 5.2.2. Analysis by Company Size
    • 5.2.3. Analysis by Geography
  • 5.3. Key Players: Analysis by Number of Product Candidates
  • 5.4. Big Pharma Initiatives

6. KEY COMMERCIALIZATION STRATEGIES

  • 6.1. Chapter Overview
  • 6.2. Successful Drug Launch Strategy: ROOTS Framework
  • 6.3. Successful Drug Launch Strategy: Product Differentiation
  • 6.4. Commonly Adopted Commercialization Strategies based on the Development Stage of the Product
  • 6.5. Approved Non-hormonal Prescription Drugs
  • 6.6. Key Commercialization Strategies Adopted by Companies Focused on Women's Health
    • 6.6.1. Strategies Adopted Before Therapy Approval
      • 6.6.1.1. Participation in Global Events
      • 6.6.1.2. Collaboration with Industry Stakeholders and Other Pharmaceutical Firms
      • 6.6.1.3. Expansion of Target Indication
    • 6.6.2. Strategies Adopted During / Post Therapy Approval
      • 6.6.2.1. Geographical Expansion
      • 6.6.2.2. Participation in Global Events
      • 6.6.2.3. Patient Assistance Programs
      • 6.6.2.4. Awareness Through Product Websites
      • 6.6.2.5. Collaboration with Industry Stakeholders and Other Pharmaceutical Firms
      • 6.6.2.6. Aligning with Government Initiatives to Ensure High Adoption Rate
  • 6.7. Concluding Remarks

7. DRUG PROFILES (PHASE III)

  • 7.1. Chapter Overview
  • 7.2. Relugolix
  • 7.3. DARE-BV1 (Clindamycin gel)
  • 7.4. Ovaprene®
  • 7.5. Yselty® (Linzagolix)
  • 7.6. Fezolinetant
  • 7.7. BAY1002670 (Vilaprisan)
  • 7.8. Abaloparatide-TD
  • 7.9. Terconazole (0.4%)
  • 7.10. SCY-078 (Ibrexafungerp)
  • 7.11. VT-1161 (Oteseconazole)
  • 7.12. MV140 (Uromune)
  • 7.13. Orilissa™ (Elagolix)
  • 7.14. EVO100 (Amphora)

8. CLINICAL TRIAL ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Scope and Methodology
  • 8.3. Non-hormonal Therapies: Clinical Trial Analysis
    • 8.3.1. Analysis by Trial Registration Year
    • 8.3.2. Analysis by Trial Status
    • 8.3.3. Analysis by Trial Phase
    • 8.3.4. Analysis by Trial Registration Year and Trial Status
    • 8.3.5. Analysis by Target Patient Segment
    • 8.3.6. Analysis by Target Indication
    • 8.3.7. Analysis by Type of Sponsor
    • 8.3.8. Analysis by Geography
      • 8.3.8.1. Analysis by Geography (Pre-2017 and Post 2017)
  • 8.4. Non-Hormonal Therapies: Analysis by Enrolled Patient Population
    • 8.4.1. Analysis by Trial Registration Year
    • 8.4.2. Analysis by Trial Status
    • 8.4.3. Analysis by Trial Phase
    • 8.4.4. Analysis by Geography
      • 8.4.4.1. Analysis by Geography (Pre-2017 and Post 2017)
  • 8.5. Analysis by Study Design
  • 8.6. Concluding Remarks
    • 8.6.1. Emerging Molecules to Watch
    • 8.6.2. Most Important Trials to Watch

9. RECENT DEVELOPMENTS

  • 9.1. Chapter Overview
  • 9.2. Partnership Models
  • 9.3. Non-hormonal Therapies: Recent Partnerships
    • 9.3.1. Analysis by Year of Partnership
    • 9.3.2. Analysis by Type of Partnership
    • 9.3.3. Analysis by Target Indication
    • 9.3.4. Most Active Players: Analysis by Number of Partnerships
    • 9.3.5. Geographical Analysis
      • 9.3.5.1. Intercontinental and Intracontinental Agreements
  • 9.4. Types of Funding
  • 9.5. Non-Hormonal Therapies: Funding and Investment Analysis
    • 9.5.1. Analysis by Number of Funding Instances
    • 9.5.2. Analysis by Amount Invested
    • 9.5.3. Analysis by Type of Funding
    • 9.5.4. Analysis by Type of Funding and Year
    • 9.5.5. Analysis by Funding Amount and Year
    • 9.5.6. Regional Analysis by Amount Invested
    • 9.5.7. Most Active Players
  • 9.6. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Limitations
  • 10.3. Key Assumptions and Forecast Methodology
  • 10.4. Global Non-hormonal Therapiesfor Women's Health Market
    • 10.4.1. Non-hormonal Therapies Market: Analysis by Target Indication
    • 10.4.2. Non-hormonal Therapies Market: Analysis by Type of Molecule
    • 10.4.3. Non-hormonal Therapies Market: Analysis by Route of Administration
    • 10.4.4. Non-hormonal Therapies Market: Analysis by Geography
  • 10.5. Non-hormonal Therapies for Women's Health Market: Value Creation Analysis
    • 10.5.1. Bacterial Vaginosis
    • 10.5.2. Contraception
    • 10.5.3. Endometriosis
    • 10.5.4. Postmenopausal Osteoporosis
    • 10.5.5. Uterine Fibroids
    • 10.5.6. Vasomotor Symptoms
  • 10.6. Non-hormonal Therapies for Women's Health Market: Product Wise Sales Forecasts
    • 10.6.1. Nuvessa™ (Metronidazole)
      • 10.6.1.1. Target Patient Population
      • 10.6.1.2. Sales Forecast
      • 10.6.1.3. Net Present Value
    • 10.6.2. VivaGel™ (SPL 7013)
      • 10.6.2.1. Target Patient Population
      • 10.6.2.2. Sales Forecast
      • 10.6.2.3. Net Present Value
    • 10.6.3. Solosec™ (Secnidazole)
      • 10.6.3.1. Target Patient Population
      • 10.6.3.2. Sales Forecast
      • 10.6.3.3. Net Present Value
    • 10.6.4. Tymlos™ (Abaloparatide)
      • 10.6.4.1. Target Patient Population
      • 10.6.4.2. Sales Forecast
      • 10.6.4.3. Net Present Value
    • 10.6.5. Orilissa™
      • 10.6.5.1. Target Patient Population
      • 10.6.5.2. Sales Forecast
      • 10.6.5.3. Net Present Value
    • 10.6.6. Osphena® (Ospemifene)
      • 10.6.6.1. Target Patient Population
      • 10.6.6.2. Sales Forecast
      • 10.6.6.3. Net Present Value
    • 10.6.7. Evenity™(Romosozumab-aqqg)
      • 10.6.7.1. Target Patient Population
      • 10.6.7.2. Sales Forecast
      • 10.6.7.3. Net Present Value
    • 10.6.8. Esmya® and Fibristal® (Ulipristal acetate)
      • 10.6.8.1. Target Patient Population
      • 10.6.8.2. Sales Forecast
      • 10.6.8.3. Net Present Value
    • 10.6.9. Phexxi™ (Amphora)
      • 10.6.9.1. Target Patient Population
      • 10.6.9.2. Sales Forecast
      • 10.6.9.3. Net Present Value
    • 10.6.10. Oriahnn™
      • 10.6.10.1. Target Patient Population
      • 10.6.10.2. Sales Forecast
      • 10.6.10.3. Net Present Value
    • 10.6.11. Relugolix
      • 10.6.11.1. Target Patient Population
      • 10.6.11.2. Sales Forecast
      • 10.6.11.3. Net Present Value
    • 10.6.12. DARE-BV1 (Clindamycin gel)
      • 10.6.12.1. Target Patient Population
      • 10.6.12.2. Sales Forecast
      • 10.6.12.3. Net Present Value
    • 10.6.13. Ovaprene®
      • 10.6.13.1. Target Patient Population
      • 10.6.13.2. Sales Forecast
      • 10.6.13.3. Net Present Value
    • 10.6.14. Yselty® (Linzagolix)
      • 10.6.14.1. Target Patient Population
      • 10.6.14.2. Sales Forecast
      • 10.6.14.3. Net Present Value
    • 10.6.15. Fezolinetant
      • 10.6.15.1. Target Patient Population
      • 10.6.15.2. Sales Forecast
      • 10.6.15.3. Net Present Value
    • 10.6.16. BAY1002670 (Vilaprisan)
      • 10.6.16.1. Target Patient Population
      • 10.6.16.2. Sales Forecast
      • 10.6.16.3. Net Present Value
    • 10.6.17. Abaloparatide-TD
      • 10.6.17.1. Target Patient Population
      • 10.6.17.2. Sales Forecast
      • 10.6.17.3. Net Present Value
    • 10.6.18. Terconazole(0.4%)
      • 10.6.18.1. Target Patient Population
      • 10.6.18.2. Sales Forecast
      • 10.6.18.3. Net Present Value
    • 10.6.19. SCY-078 (Ibrexafungerp)
      • 10.6.19.1. Target Patient Population
      • 10.6.19.2. Sales Forecast
      • 10.6.19.3. Net Present Value
    • 10.6.20. VT-1161 (Oteseconazole)
      • 10.6.20.1. Target Patient Population
      • 10.6.20.2. Sales Forecast
      • 10.6.20.3. Net Present Value
    • 10.6.21. MV140 (Uromune)
      • 10.6.21.1. Target Patient Population
      • 10.6.21.2. Sales Forecast
      • 10.6.21.3. Net Present Value
    • 10.6.22. EVO100
      • 10.6.22.1. Target Patient Population
      • 10.6.22.2. Sales Forecast
      • 10.6.22.3. Net Present Value

11. CONCLUDING REMARKS

12. APPENDIX 1: TABULATED DATA

13. APPENDIX 2: LIST OF COMPANIES

List Of Figures

  • Figure 3.1 Key Milestones in the Treatment of Women's Health-related Disorders
  • Figure 3.2 Women's Health-related Conditions
  • Figure 3.3 Available Treatment Modalities: Non-hormonal Therapies
  • Figure 4.1 Non-hormonal Therapies: Distribution by Phase of Development
  • Figure 4.2 Non-hormonal Therapies: Distribution by Type of Molecule
  • Figure 4.3 Non-hormonal Therapies: Distribution by Target Indication
  • Figure 4.4 Non-hormonal Therapies: Distribution by Phase of Development and Target Indication
  • Figure 4.5 Non-hormonal Therapies: Distribution by Type of Molecule and Target Indication
  • Figure 4.6 Non-hormonal Therapies: Distribution by Purpose of Therapy
  • Figure 4.7 Non-hormonal Therapies: Distribution by Target Women Population
  • Figure 4.8 Non-hormonal Therapies: Distribution by Mechanism of Action
  • Figure 4.9 Non-hormonal Therapies: Distribution by Route of Administration
  • Figure 4.10 Non-hormonal Therapies: Distribution by Special Designation(s) Awarded
  • Figure 5.1 Non-hormonal Therapy Developers: Distribution by Year of Establishment
  • Figure 5.2 Non-hormonal Therapy Developers: Distribution by Company Size
  • Figure 5.3 Non-hormonal Therapy Developers: Distribution by Location of Headquarters
  • Figure 5.4 Non-hormonal Therapy Developers: Distribution by Year of Establishment, Company Size and Location of Headquarters
  • Figure 5.5 Non-hormonal Therapy Developers: Big Pharma Initiatives
  • Figure 6.1 Successful Drug Launch Strategy: ROOTS Framework
  • Figure 6.2 Successful Drug Launch Strategy: Product Differentiation
  • Figure 6.3 Commonly Adopted Commercialization Strategies based on Development Stage of the Product
  • Figure 6.4 Harvey Ball Analysis: Commercialization Strategies Adopted by Companies Focused on Women's Health
  • Figure 6.5 Approved Non-hormonal Prescription Drugs: Snapshot of Promotional Activities on Product Websites
  • Figure 6.6 Key Commercialization Strategies: Harvey Ball Analysis by Ease of Implementation, Value Addition and Current Adoption
  • Figure 8.1 Clinical Trial Analysis: Cumulative Distribution by Trial Registration Year, Pre 2013-2020
  • Figure 8.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 8.3 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 8.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Figure 8.5 Clinical Trial Analysis: Distribution by Target Patient Segment
  • Figure 8.6 Clinical Trial Analysis: Distribution by Target Indication
  • Figure 8.7 Clinical Trial Analysis: Distribution by Type of Sponsor
  • Figure 8.8 Clinical Trial Analysis: Distribution by Geography
  • Figure 8.9 Clinical Trial Analysis: Distribution by Geography,Pre-2017 and Post-2017
  • Figure 8.10 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
  • Figure 8.11 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Status
  • Figure 8.12 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Phase
  • Figure 8.13 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Location of Trial Site
  • Figure 8.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography, Pre-2017 and Post 2017
  • Figure 8.15 Clinical Trial Analysis: Distribution by Study Design
  • Figure 9.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2021
  • Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 9.3 Partnerships and Collaborations: Cumulative Trend by Year and Type of Collaboration, 2013-2021
  • Figure 9.4 Partnerships and Collaborations: Distribution by Type of Merger / Acquisition
  • Figure 9.5 Partnerships and Collaborations: Distribution by Focus Area
  • Figure 9.6 Partnerships and Collaborations: Distribution by Target Indication
  • Figure 9.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 9.8 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Figure 9.9 Funding and Investment Analysis: Cumulative Year-wise Distribution by Number of Instances, 2016-2020
  • Figure 9.10 Funding and Investment Analysis: Cumulative Year-wise Distribution of Amount Invested, 2016-2020 (USD Million)
  • Figure 9.11 Funding and Investment Analysis: Distribution by Type of Funding
  • Figure 9.12 Funding and Investment Analysis: Distribution by Year and Type of Funding
  • Figure 9.13 Funding and Investment Analysis: Distribution by Year and Funding Amount (USD Million)
  • Figure 9.14 Funding and Investment Analysis: Summary of Investments, 2016-2020 (USD Million)
  • Figure 9.15 Funding and Investment Analysis: Distribution by Geography
  • Figure 9.16 Funding and Investment Analysis: Regional Distribution of Funding Instances
  • Figure 9.17 Most Active Players: Distribution by Number of Funding Instances, 2016-2020
  • Figure 9.18 Most Active Players: Distribution by Amount Invested, 2016-2020 (USD Million)
  • Figure 9.19 Funding and Investment Summary, 2016-2020 (USD Million)
  • Figure 10.1 Global Non-hormonal Therapies for Women's Health Market, 2021-2030: Base Case Scenario (USD Million)
  • Figure 10.2 Non-hormonal Therapies Market: Distribution by Target Indication, 2021, 2025 and 2030
  • Figure 10.3 Non-hormonal Therapies Market: Distribution by Type of Molecule, 2021, 2025 and 2030
  • Figure 10.4 Non-hormonal Therapies Market: Distribution by Route of Administration, 2021, 2025 and 2030
  • Figure 10.5 Non-hormonal Therapies Market: Distribution by Geography, 2021, 2025 and 2030
  • Figure 10.6 Nuvessa™Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.7 VivaGel™ Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.8 Solosec™ Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.9 Tymlos™ Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.10 Orilissa™ Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.11 Osphena® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.12 Evenity™ Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.13 Esmya® and Fibristal®Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.14 Phexxi™ Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.15 Oriahnn™ Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.16 Relugolix Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.17 DARE-BV1 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.18 Ovaprene® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.19 Yselty® Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.20 Fezolinetant Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.21 BAY1002670 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.22 Abaloparatide-TD Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.23 Terconazole (0.4%) Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.24 SCY-078 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.25 VT-1161 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.26 MV140 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 10.27 EVO100 Sales Forecast (Till 2030): Base Scenario (USD Million)
  • Figure 11.1 Concluding Remarks: Summary of the Current Market Landscape
  • Figure 11.2 Concluding Remarks: Summary of the Current Developer Landscape
  • Figure 11.3 Concluding Remarks: Summary of Recent Developments
  • Figure 11.4 Concluding Remarks: Market Sizing and Opportunity Analysis